Home Cart Sign in  
Chemical Structure| 1353900-92-1 Chemical Structure| 1353900-92-1

Structure of Pibrentasvir
CAS No.: 1353900-92-1

Chemical Structure| 1353900-92-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pibrentasvir is a protease inhibitor potentially for the treatment of HCV infection.

Synonyms: ABT-530

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pibrentasvir

CAS No. :1353900-92-1
Formula : C57H65F5N10O8
M.W : 1113.18
SMILES Code : FC1=C([C@@H]2N([C@H](CC2)C3=C(F)C=C4C(NC([C@@H]5CCCN5C([C@@H](NC(OC)=O)[C@H](OC)C)=O)=N4)=C3)C6=CC(F)=C(C(F)=C6)N7CCC(CC7)C8=CC=C(C=C8)F)C=C9C(N=C(N9)[C@@H]%10CCCN%10C([C@@H](NC(OC)=O)[C@H](OC)C)=O)=C1
Synonyms :
ABT-530
MDL No. :MFCD30747902
InChI Key :VJYSBPDEJWLKKJ-NLIMODCCSA-N
Pubchem ID :58031952

Safety of Pibrentasvir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh-7 (genotype 1a replicon) 1.8 pM 3 days Evaluate the antiviral activity of Pibrentasvir against HCV genotype 1a replicon, EC50 was 1.8 pM PMC5404558
A549 hACE2 TMPRSS2 cells 0.625 µM 48 h To evaluate the inhibitory effect of Pibrentasvir on SARS-CoV-2 infection, results showed inhibition of over 90% of infection at the lowest concentration of 0.625 µM. PMC10534768
Huh7.5 cells 0.05 nM 30 days Evaluate the efficacy and barrier to resistance of Pibrentasvir against HCV genotypes 2a, 2b, and 2c, showing high efficiency in eradicating HCV infections in combination therapy. PMC7038289

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice SARS-CoV-2 B.1.351 infection model Intraperitoneal injection 24 mg/kg Once daily for 4 days To evaluate the prophylactic effect of Pibrentasvir in a SARS-CoV-2 infected mouse model, results showed no significant reduction in viral replication or weight loss. PMC10534768

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.90mL

0.18mL

0.09mL

4.49mL

0.90mL

0.45mL

8.98mL

1.80mL

0.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories